File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ejca.2014.06.011
- Scopus: eid_2-s2.0-85027947584
- PMID: 25027307
- WOS: WOS:000341449200001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer
Title | A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer |
---|---|
Authors | |
Keywords | AMH Breast cancer Chemotherapy Ovarian function Ovarian reserve |
Issue Date | 2014 |
Publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca |
Citation | European Journal of Cancer, 2014, v. 50 n. 14, p. 2367-2374 How to Cite? |
Abstract | AIM:
Anti-Müllerian hormone (AMH) shows promise as a biomarker of the ovarian reserve but current assays are insufficiently sensitive to allow assessment of this post-chemotherapy in most women. We have assessed a new highly sensitive AMH assay (Ansh picoAMH) in the evaluation of ovarian activity in women with very low ovarian reserve after chemotherapy.
METHODS:
A prospective cohort and an independent validation cohort of premenopausal women with early breast cancer (eBC) were recruited at the time of diagnosis (combined n=98), and ovarian reserve markers 2-5 years later following chemotherapy were assessed in relation to menstrual activity.
RESULTS:
The picoAMH assay had a limit of detection of 7.5 pg/ml. AMH clearly distinguished women with ongoing menses from those with amenorrhoea at 2 years after diagnosis (mean 522 ± 169 versus 8.9 ± 1.3 pg/ml, P<0.0001) with high predictive value for continuing menses or amenorrhoea for the subsequent 3 years. AMH was detectable in more women than using a previous assay (P=0.004). Other markers of the ovarian reserve (follicle-stimulating hormone (FSH), inhibin B) were also of discriminatory value but to lesser extents. This finding was validated in a second, independent cohort of women treated for eBC.
CONCLUSION:
The 10-fold increased assay sensitivity showed very clear distinction between groups based on ovarian activity with excellent prediction of future menses or amenorrhoea. This will improve assessment of post-chemotherapy ovarian function in women and may aid treatment decisions.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/201052 |
ISSN | 2023 Impact Factor: 7.6 2023 SCImago Journal Rankings: 2.501 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chai, J | - |
dc.contributor.author | Howie, AF | - |
dc.contributor.author | Cameron, DA | - |
dc.contributor.author | Anderson, RA | - |
dc.date.accessioned | 2014-08-21T07:10:56Z | - |
dc.date.available | 2014-08-21T07:10:56Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | European Journal of Cancer, 2014, v. 50 n. 14, p. 2367-2374 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | http://hdl.handle.net/10722/201052 | - |
dc.description.abstract | AIM: Anti-Müllerian hormone (AMH) shows promise as a biomarker of the ovarian reserve but current assays are insufficiently sensitive to allow assessment of this post-chemotherapy in most women. We have assessed a new highly sensitive AMH assay (Ansh picoAMH) in the evaluation of ovarian activity in women with very low ovarian reserve after chemotherapy. METHODS: A prospective cohort and an independent validation cohort of premenopausal women with early breast cancer (eBC) were recruited at the time of diagnosis (combined n=98), and ovarian reserve markers 2-5 years later following chemotherapy were assessed in relation to menstrual activity. RESULTS: The picoAMH assay had a limit of detection of 7.5 pg/ml. AMH clearly distinguished women with ongoing menses from those with amenorrhoea at 2 years after diagnosis (mean 522 ± 169 versus 8.9 ± 1.3 pg/ml, P<0.0001) with high predictive value for continuing menses or amenorrhoea for the subsequent 3 years. AMH was detectable in more women than using a previous assay (P=0.004). Other markers of the ovarian reserve (follicle-stimulating hormone (FSH), inhibin B) were also of discriminatory value but to lesser extents. This finding was validated in a second, independent cohort of women treated for eBC. CONCLUSION: The 10-fold increased assay sensitivity showed very clear distinction between groups based on ovarian activity with excellent prediction of future menses or amenorrhoea. This will improve assessment of post-chemotherapy ovarian function in women and may aid treatment decisions. Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved. | - |
dc.language | eng | - |
dc.publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca | - |
dc.relation.ispartof | European Journal of Cancer | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | AMH | - |
dc.subject | Breast cancer | - |
dc.subject | Chemotherapy | - |
dc.subject | Ovarian function | - |
dc.subject | Ovarian reserve | - |
dc.title | A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer | - |
dc.type | Article | - |
dc.identifier.email | Chai, J: jchai@hkucc.hku.hk | - |
dc.identifier.authority | Chai, J=rp00241 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1016/j.ejca.2014.06.011 | - |
dc.identifier.pmid | 25027307 | - |
dc.identifier.pmcid | PMC4166459 | - |
dc.identifier.scopus | eid_2-s2.0-85027947584 | - |
dc.identifier.hkuros | 234827 | - |
dc.identifier.hkuros | 253799 | - |
dc.identifier.volume | 50 | - |
dc.identifier.issue | 14 | - |
dc.identifier.spage | 2367 | - |
dc.identifier.epage | 2374 | - |
dc.identifier.isi | WOS:000341449200001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0959-8049 | - |